Managed Healthcare Executive November 5, 2019
The race to decrease drug costs is heating up across America. The Trump Administration has one idea, House Majority Leader Nancy Pelosi has her solution and Big Pharma has prosed a resolution to the problem. But some insurers are now rising to the occasion and finding ways for members to afford expensive specialty drug treatments, such as gene therapy.
The cost of gene therapies is expected to reach more than $16 billion in the United States by 2024. While only two therapies have yet to be approved, they are indicative of the high price tag.
Luxturna (voretigene neparvovec-rzyl), the first FDA-approved prescription gene therapy for people with inherited retinal disease leading to blindness, costs $415,000 per eye. Zolgensma (onasemnogene abeparvovec-xioi)...
Today's Sponsors
Today's Sponsor